• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物相关性颌骨坏死(MRONJ):病理生理学、危险因素、预防措施及治疗策略综述

Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies.

作者信息

AlRowis Raed, Aldawood Abdulmalik, AlOtaibi Mohammed, Alnasser Essam, AlSaif Ibrahim, Aljaber Abdullah, Natto Zuhair

机构信息

Department of Periodontics and Community Dentistry, College of Dentistry, King Saud University, Saudi Arabia.

Intern. College of Dentistry, King Saud University, Saudi Arabia.

出版信息

Saudi Dent J. 2022 Mar;34(3):202-210. doi: 10.1016/j.sdentj.2022.01.003. Epub 2022 Jan 19.

DOI:10.1016/j.sdentj.2022.01.003
PMID:35935720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9346931/
Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a major problem that can occur in people taking certain medications such bisphosphonates and denosumab. It can be used to treat osteoporosis or cancer. Bisphosphonate exposure, dental diseases and procedures, age, sex, anatomical factors, medical issues, and hereditary factors are all variables that enhance the risk of MRONJ. Even though MRONJ and antiresorptive medications have a close association, the pathophysiology of MRONJ is unknown. Careful dental preparation and oral hygiene instructions significantly minimize the risk of osteonecrosis of the jaw (ONJ). It is ideal to start antiresorptive treatment after the completion of required dental treatment; it is not contraindicated and carries low risk in patients who are on oral antiresorptive medications for less than three years. Drug holidays are one proposed solution to address MRONJ. However, there is still inadequate evidence to support their effectiveness. The objectives of this literature review are to recognize the main diagnostic principles and risk factors and to review the pathophysiology, protective procedures and treatment modalities related to MRONJ. The following topics are covered in the review: epidemiology, diagnostic criteria, risk factors, pathogenesis and mechanism, MRONJ staging and symptoms, clinical and radiographic findings, treatment strategies, prevention and drug holiday.

摘要

药物相关性颌骨坏死(MRONJ)是服用某些药物(如双膦酸盐和地诺单抗)的人可能出现的一个主要问题。这些药物可用于治疗骨质疏松症或癌症。双膦酸盐暴露、牙科疾病及操作、年龄、性别、解剖因素、医疗问题和遗传因素都是增加MRONJ风险的变量。尽管MRONJ与抗吸收药物密切相关,但其病理生理学尚不清楚。仔细的牙科准备和口腔卫生指导可显著降低颌骨坏死(ONJ)的风险。理想情况下,应在完成所需的牙科治疗后开始抗吸收治疗;对于服用口服抗吸收药物少于三年的患者,这并非禁忌且风险较低。药物假期是针对MRONJ提出的一种解决方案。然而,仍缺乏足够的证据支持其有效性。这篇文献综述的目的是识别主要的诊断原则和风险因素,并回顾与MRONJ相关的病理生理学、防护措施和治疗方式。综述涵盖以下主题:流行病学、诊断标准、风险因素、发病机制、MRONJ分期及症状、临床和影像学表现、治疗策略、预防和药物假期。

相似文献

1
Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies.药物相关性颌骨坏死(MRONJ):病理生理学、危险因素、预防措施及治疗策略综述
Saudi Dent J. 2022 Mar;34(3):202-210. doi: 10.1016/j.sdentj.2022.01.003. Epub 2022 Jan 19.
2
[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].[关于药物性颌骨坏死(MRONJ)的立场文件]
Wien Med Wochenschr. 2016 Feb;166(1-2):68-74. doi: 10.1007/s10354-016-0437-2.
3
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.药物相关性颌骨坏死的临床注意事项:全面文献回顾。
Int J Implant Dent. 2021 May 14;7(1):47. doi: 10.1186/s40729-021-00323-0.
4
Medication-related osteonecrosis of the jaw: A literature review.药物相关性颌骨坏死:文献综述
J Oral Biosci. 2019 Jun;61(2):99-104. doi: 10.1016/j.job.2019.03.005. Epub 2019 May 15.
5
Emerging antiresorptive medications and their potential implications for dental surgeries.新兴的抗吸收药物及其对牙科手术的潜在影响。
J Am Dent Assoc. 2022 Jul;153(7):649-658. doi: 10.1016/j.adaj.2021.12.008. Epub 2022 Mar 8.
6
Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy.对有发生颌骨药物相关性骨坏死(MRONJ)风险患者的认知——一项一级预防策略。
Saudi Pharm J. 2020 Jun;28(6):771-778. doi: 10.1016/j.jsps.2020.05.004. Epub 2020 May 15.
7
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.颌骨骨坏死与良性及恶性疾病中的抗吸收药物:由 ECTS 组织的批判性回顾。
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1441-1460. doi: 10.1210/clinem/dgab888.
8
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.药物性颌骨坏死的发生率及其相关危险因素。
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9.
9
The effect of drug holiday on preventing medication-related osteonecrosis of the jaw in osteoporotic rat model.药物假期对骨质疏松大鼠模型中预防药物相关性颌骨坏死的作用。
J Orthop Translat. 2023 Jan 10;39:55-62. doi: 10.1016/j.jot.2022.12.006. eCollection 2023 Mar.
10
Is it safe to place implants in patients at risk of MRONJ?在有发生下颌骨放射性骨坏死风险的患者中植入种植体是否安全?
Evid Based Dent. 2021 Jan;22(3):108-109. doi: 10.1038/s41432-021-0196-9.

引用本文的文献

1
Autologous Platelet Concentrates in the Management of Medication-Related Osteonecrosis of the Jaw: A Systematic Review.自体血小板浓缩物在药物相关性颌骨坏死治疗中的应用:一项系统评价
Medicina (Kaunas). 2025 Aug 21;61(8):1496. doi: 10.3390/medicina61081496.
2
Comprehensive Review of Prevention and Management Strategies for Medication-related Osteonecrosis of the Jaw (MRONJ).颌骨药物性骨坏死(MRONJ)预防与管理策略的综合综述
Oral Health Prev Dent. 2025 Aug 5;23:403-417. doi: 10.3290/j.ohpd.c_2169.
3
What is the appropriate antibiotic administration to prevent MRONJ development after tooth extraction?拔牙后预防药物相关性颌骨坏死(MRONJ)发生的合适抗生素给药方式是什么?
J Bone Miner Metab. 2025 Jul 2. doi: 10.1007/s00774-025-01617-8.
4
A case series and review of canine idiopathic osteonecrosis of the jaw.犬颌骨特发性骨坏死的病例系列及综述
Front Vet Sci. 2025 May 27;12:1614645. doi: 10.3389/fvets.2025.1614645. eCollection 2025.
5
Photobiomodulation in Medication-Related Osteonecrosis of the Jaw: Outcomes in Stage I and Its Adjunctive Role in Advanced Cases.光生物调节在药物相关性颌骨坏死中的应用:I期治疗效果及其在晚期病例中的辅助作用
Biomedicines. 2025 Apr 25;13(5):1042. doi: 10.3390/biomedicines13051042.
6
Recent Stem-Cell-Based and Stem-Cell-Free Possibilities for the Therapeutic Management of the Osteonecrosis of the Jaw.基于干细胞及无干细胞疗法治疗颌骨坏死的最新进展
Biomolecules. 2025 Apr 16;15(4):595. doi: 10.3390/biom15040595.
7
Prevalence of MRONJ in patients treated with antiresorptive agents for glucocorticoid-induced osteoporosis.接受抗吸收药物治疗糖皮质激素性骨质疏松症患者的下颌骨坏死患病率。
Oral Maxillofac Surg. 2025 Apr 16;29(1):84. doi: 10.1007/s10006-025-01383-x.
8
The issue with incidence: a scoping review of reported medication-related osteonecrosis of the jaws (MRONJ) incidence around the globe.发病率问题:全球范围内已报道的颌骨药物相关性骨坏死(MRONJ)发病率的范围综述。
BMJ Public Health. 2025 Apr 5;3(1):e002009. doi: 10.1136/bmjph-2024-002009. eCollection 2025.
9
The Microbiological Background of Medication-Related Osteonecrosis of the Jaw (MRONJ): Clinical Evidence Based on Traditional Culture and Molecular Biological Detection Methods.颌骨药物相关性骨坏死(MRONJ)的微生物学背景:基于传统培养和分子生物学检测方法的临床证据
Antibiotics (Basel). 2025 Feb 15;14(2):203. doi: 10.3390/antibiotics14020203.
10
Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol.己酮可可碱与生育酚对药物相关性颌骨坏死(MRONJ)的药物治疗
J Clin Med. 2025 Feb 3;14(3):974. doi: 10.3390/jcm14030974.

本文引用的文献

1
Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.序贯抗吸收药物治疗患者药物相关性颌骨坏死的患病率:系统评价和荟萃分析。
Support Care Cancer. 2021 May;29(5):2305-2317. doi: 10.1007/s00520-020-05882-3. Epub 2020 Nov 15.
2
A Drug Holiday Reduces the Frequency and Severity of Medication-Related Osteonecrosis of the Jaw in a Minipig Model.药物假期可降低小型猪模型中药物相关性颌骨坏死的发生率和严重程度。
J Bone Miner Res. 2020 Nov;35(11):2179-2192. doi: 10.1002/jbmr.4119. Epub 2020 Aug 10.
3
Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.患有骨转移乳腺癌的女性中与药物相关的颌骨坏死的发生率和危险因素:一项基于人群的研究。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Sep;130(3):252-257. doi: 10.1016/j.oooo.2020.04.808. Epub 2020 Jun 12.
4
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.阿仑膦酸钠或唑来膦酸并不影响绝经后骨质疏松症女性拔牙后伤口愈合。
Bone. 2020 Aug;137:115412. doi: 10.1016/j.bone.2020.115412. Epub 2020 May 20.
5
Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.接受地舒单抗和唑来膦酸治疗的癌症患者的药物相关性颌骨坏死(MRONJ):系统评价和荟萃分析。
Med Oral Patol Oral Cir Bucal. 2020 May 1;25(3):e326-e336. doi: 10.4317/medoral.23324.
6
Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw.自体富血小板纤维蛋白注射治疗药物相关性颌骨坏死继发面部皮肤窦道
Dermatol Ther. 2020 May;33(3):e13334. doi: 10.1111/dth.13334. Epub 2020 Apr 2.
7
New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws.托珠单抗治疗新冠病毒病患者的新治疗机遇:白细胞介素-6受体抑制剂与颌骨坏死的可能关联
Oral Oncol. 2020 Jul;106:104659. doi: 10.1016/j.oraloncology.2020.104659. Epub 2020 Mar 21.
8
Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review.血小板浓缩物在预防和治疗药物相关性颌骨坏死中的应用是否有效?系统评价。
J Craniomaxillofac Surg. 2020 Mar;48(3):268-285. doi: 10.1016/j.jcms.2020.01.014. Epub 2020 Feb 3.
9
Dental Students' Knowledge and Attitudes About Electronic Cigarettes: A Cross-Sectional Study at One Saudi University.《沙特某大学一项横断面研究:关于电子烟,牙科学子的知识和态度》。
J Dent Educ. 2020 Jan;84(1):27-33. doi: 10.21815/JDE.019.162.
10
Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.骨质疏松症和乳腺癌患者药物相关性颌骨坏死的患病率和危险因素:一项横断面研究。
Support Care Cancer. 2020 May;28(5):2265-2271. doi: 10.1007/s00520-019-05044-0. Epub 2019 Aug 29.